Fundraising FoxAmbit Biosciences Corporation
acquired by Daiichi Sankyo2 known investors
Find your way into Ambit Biosciences Corporation
Sign up to see every warm intro you have to Ambit Biosciences Corporation
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ambit Biosciences Corporation team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Daiichi Sankyo October 2014 · $315M ($15.00 per share cash plus CVR; ~$315M upfront, up to $410M total with milestones) · source ↗
Ambit Biosciences was a San Diego biopharmaceutical company developing small-molecule kinase inhibitors, including quizartinib, a FLT3 inhibitor for acute myeloid leukemia.
Investors · 2
Frequently asked questions
- What does Ambit Biosciences Corporation do?
- Ambit Biosciences was a San Diego biopharmaceutical company developing small-molecule kinase inhibitors, including quizartinib, a FLT3 inhibitor for acute myeloid leukemia.
- Who are Ambit Biosciences Corporation's investors?
- Ambit Biosciences Corporation's investors include Aisling Capital, Foresite Capital.
- Who acquired Ambit Biosciences Corporation?
- Ambit Biosciences Corporation was acquired by Daiichi Sankyo.